Menu
Open submenu (Categories)
Categories
Write for Us
Spotlight TV
Ophthalmology Glossary
Submit
Press Release
Close submenu
Categories
Breaking News
Industry News
Ophthalmic Blog
Ophthalmic Research News
We use cookies so that we can give you the best experience on our website. If you continue to use this site, we assume that you accept it.
Accept
Categories
Breaking News
Industry News
Ophthalmic Blog
Ophthalmic Research News
Write for Us
Spotlight TV
Ophthalmology Glossary
Subscribe
FDA Expands Luminopia’s Label to Include Amblyopia Patients Aged 8 to 12
Study Highlights Need for Early Advice to Young Adults Amid Rising Dry Eye Disease Cases
Researchers Identify Molecular Link Between HPV and Thyroid Eye Disease
Palatin Releases Updated Responder Analysis Results from Phase 3 Melody-1 Trial in Dry Eye Disease
Ace Vision Group Closes $29.4 Million Series B Financing to Advance Presbyopia Laser Technology
FDA Expands Luminopia’s Label to Include Amblyopia Patients Aged 8 to 12
Study Highlights Need for Early Advice to Young Adults Amid Rising Dry Eye Disease Cases
Researchers Identify Molecular Link Between HPV and Thyroid Eye Disease
Palatin Releases Updated Responder Analysis Results from Phase 3 Melody-1 Trial in Dry Eye Disease
Ace Vision Group Closes $29.4 Million Series B Financing to Advance Presbyopia Laser Technology
FDA Expands Luminopia’s Label to Include Amblyopia Patients Aged 8 to 12
Recommended
March 14, 2025
OBN Spotlight TV: Interview with Jeff Todd, President & CEO of Prevent Blindness
Breaking News
FDA Expands Luminopia’s Label to Include Amblyopia Patients Aged 8 to 12
Apr 30, 2025
Luminopia has announced that the U.S. Food and Drug Administration (FDA) has expanded the label of its amblyopia treatment to include patients aged 8 to 12 years, broadening its previous indication.
FDA Issues Complete Response Letter to Regeneron for EYLEA HD sBLA on Extended Dosing Intervals
Apr 22, 2025
Regeneron Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its supplemental Biologics License Application (sBLA) for EYLEA HD (aflibercept 8 mg).
BVI Medical Receives FDA 510(k) Clearance for Leos Glaucoma Surgical System
Apr 18, 2025
BVI Medical has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative glaucoma surgical platform, the Laser Endoscopy Ophthalmic System (Leos).
Industry News
Palatin Releases Updated Responder Analysis Results from Phase 3 Melody-1 Trial in Dry Eye Disease
Apr 30, 2025
Palatin Technologies has announced updated results from responder analyses of its pivotal Phase 3 Melody-1 clinical trial, which evaluated the safety and efficacy of PL9643 compared to placebo in the treatment of dry eye disease (DED).
Ace Vision Group Closes $29.4 Million Series B Financing to Advance Presbyopia Laser Technology
Apr 30, 2025
Ace Vision Group (AVG) has announced the successful closing of a $29.4 million Series B financing round.
UNITY Biotechnology Announces NEJM Evidence Publication of Phase 2 UBX1325 Data in DME
Apr 29, 2025
UNITY Biotechnology has announced that NEJM Evidence has published results from the Phase 2 BEHOLD study, evaluating UBX1325 in patients with diabetic macular edema (DME).
Ophthalmic Research News
Study Highlights Need for Early Advice to Young Adults Amid Rising Dry Eye Disease Cases
Apr 29, 2025
Researchers at Aston University, in collaboration with Oslo University Hospital and Sørlandet Hospital Trust in Norway, have called for more preventive advice to be given to young adults regarding dry eye disease.
Researchers Identify Molecular Link Between HPV and Thyroid Eye Disease
Apr 29, 2025
Researchers from the University of Miami Miller School of Medicine have identified molecular evidence linking human papillomavirus (HPV) to thyroid eye disease (TED).
Study: Fear of Vision Loss May Deter Some Patients from Undergoing Cataract Surgery
Apr 25, 2025
A newly published study in Clinical Ophthalmology suggests that fear—particularly of losing vision—may prevent some patients from pursuing necessary cataract surgery, despite its effectiveness in reversing blindness.
Ophthalmic Blog
AI in Ophthalmology: Top Artificial Intelligence Tools Transforming Eye Health
Mar 07, 2025
The AI in ophthalmology sector is evolving rapidly, introducing Artificial Intelligence tools in ophthalmology that enhance diagnostic accuracy, efficiency, and accessibility.
2024 Recap: Top 8 Groundbreaking Innovations in Eye Disease Therapies and Technologies
Dec 23, 2024
The year 2024 has been a remarkable period for advancements in ophthalmology, with groundbreaking innovations reshaping the landscape of eye disease treatment and diagnosis.
2024 Recap: Top 8 FDA Approvals in Ophthalmology
Dec 16, 2024
The year 2024 has been a pivotal one for ophthalmology, with several novel FDA approvals introducing innovative treatments and technologies to the field
Ophthalmology Breaking News Subscribe
I agree to receive future communications from OBN, in accordance with the
Privacy Policy.